| human | Q5 |
| P496 | ORCID iD | 0000-0002-4888-1463 |
| P69 | educated at | Claude Bernard University Lyon 1 | Q4032 |
| P108 | employer | hospices civils de lyon | Q3140953 |
| P106 | occupation | researcher | Q1650915 |
| Q79754022 | A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug |
| Q89890427 | A new paradigm for personalized prophylaxis for patients with severe haemophilia A |
| Q33384200 | A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study |
| Q37185097 | Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. |
| Q50752406 | Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia. |
| Q45874701 | An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. |
| Q81577532 | An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy |
| Q36661832 | Basic aspects of bypassing agents. |
| Q51071834 | Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. |
| Q45400421 | Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient. |
| Q45880318 | Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-ge |
| Q83120292 | Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations |
| Q35126279 | Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation |
| Q52325790 | Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency. |
| Q53776850 | Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. |
| Q46676476 | Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. |
| Q33401170 | Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management |
| Q45862384 | Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements |
| Q53059020 | Do heterozygous factor V Leiden and prothrombin G20210A mutations have different impact on the type and location of venous thromboembolism? |
| Q53458479 | Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation. |
| Q40170248 | Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. |
| Q83321361 | Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor |
| Q82300158 | Endogenous thrombin potential, prothrombin fragment 1+2 and D-dimers during pregnancy |
| Q45881288 | Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study |
| Q45168592 | Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. |
| Q64992880 | Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. |
| Q38896886 | Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. |
| Q81733264 | Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women. A rebuttal |
| Q45855717 | Genotyping might help therapeutic decision-making in patients with von Willebrand disease type 2 B. |
| Q45879939 | Global haemostasis and point of care testing. |
| Q54593188 | Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: are these results really discordant? |
| Q91546335 | Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study |
| Q97551956 | Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov2 associated thrombosis |
| Q38873929 | In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7. |
| Q88944075 | Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A |
| Q88066819 | Individualized PK-based prophylaxis in severe haemophilia |
| Q28192133 | Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency |
| Q82078305 | Intraindividual thrombin generation measurement variability in healthy adults over a one year period |
| Q45886430 | Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. |
| Q81865359 | Management of pregnant women with increased risk of venous thrombosis |
| Q63367976 | Monitoring platelet dependent thrombin generation in mice |
| Q45220917 | Multiple arterial thromboses in a patient with primary antiphospholipid syndrome receiving a bromocriptine therapy. |
| Q37169669 | New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. |
| Q37768873 | New developments in laboratory diagnosis and monitoring. |
| Q45871901 | On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. |
| Q47431704 | Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study. |
| Q50801300 | Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays. |
| Q45869234 | Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. |
| Q45863275 | Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. |
| Q98830125 | Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater |
| Q98778779 | Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation? |
| Q46389324 | Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. |
| Q45865060 | Spontaneous proximal deep vein thrombosis in a patient with severe haemophilia A. |
| Q35014747 | Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. |
| Q83877768 | Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report |
| Q37768877 | Tests of global haemostasis and their applications in bleeding disorders. |
| Q45232152 | The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany |
| Q36818527 | Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. |
| Q80138561 | Thrombin-generating capacity in patients with von Willebrand's disease |
| Q79323692 | Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype |
| Q45878335 | Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. |
| Q52689204 | Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. |
| Q45879526 | Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. |
| Q47395469 | Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin? |
| Q64042536 | [Acquired factor V deficiency: a rare bleeding disorder with variable clinical presentations] |
Search more.